目的:探讨血浆和肽素水平与糖尿病患者冠心病发生率及冠状动脉病变严重程度的相关性。方法:(1) 选择2014年8月至2015年8月行冠状动脉造影检查的糖尿病患者173例,测定其血浆和肽素水平,根据患者行冠状动脉造影术前血浆和肽素水平的四分位点将其分为4组:A组44例(和肽素≤0.608 pmol·L-1),B组 43例(>0.608 pmol·L-1而≤1.497 pmol·L-1),C组43例(>1.497 pmol·L-1而≤5.483 pmol·L-1),D组43例(>5.483 pmol·L-1),比较4组之间冠心病发生率的差异。(2) 将173例患者中冠状动脉造影完全正常的患者作为对照组(n=22),根据Gensini评分标准将冠状动脉造影异常但未达到冠心病标准的61例剔除,其余冠心病患者分为轻度狭窄组(n=50,积分<20)、中度狭窄组(n=19,20≤积分<40)和重度狭窄组(n=21,积分≥40)3组,比较4组和肽素水平的差异。结果:(1) A组发生冠心病15例(34.1%),B组发生19例(44.2%),C组发生25例(58.1%),D组发生31例(72.1%),各组冠心病发生率相比较差异具有统计学意义。(2) 中、重度狭窄组血浆和肽素水平较对照组及轻度狭窄组升高,差异具有统计学意义。中度狭窄组和重度狭窄组之间血浆和肽素水平比较差异无统计学意义,对照组与轻度狭窄组之间差异无统计学意义。结论:糖尿病患者冠心病的发生率与和肽素水平呈正相关,糖尿病合并冠心病患者冠状动脉病变的严重程度与肽素水平呈正相关。 |
Objective:To investigate the correlation between plasma level of copeptin and the incidence of coronary atherosclerotic heart disease(CHD) and the severity of the coronary artery lesions in diabetics. Methods:(1) Coronary angiography(CAG) was performed in 173 diabetics from August 2014 to August 2015. The plasma level of copeptin was determined before CAG. According to the quartiles of the plasma level of copeptin, diabetics were divided into four groups:44 diabetics in group A(copeptin level≤0.608 pmol·L-1), 43 diabetics in group B(0.608 pmol·L-1-1), 43 diabetics in group C(1.497 pmol·L-1-1), 43 diabetics in group D(copeptin level>5.483 pmol·L-1). The differences of baseline data and incidence of CHD between the four groups were compared. (2) According to CAG and Gensini scroes, diabetics were divided into four groups:mild stenosis group(n=50, Gensini scroe<20), moderate stenosis group(n=19, 20≤Gensini scroes<40), severe stenosis group(n=21, Gensini scroes≥40), and normal coronary artery group as control group(n=20). The differences of plasma levels of copeptin in the four groups were compared. Results:(1) The incidence of CHD was 34.1%(15/44) in group A, 44.2%(19/43) in group B, 58.1%(25/43) in group C, 72.1%(31/43) in group D. The higher the plasma levels of copeptin, the higher the incidences of CHD(P<0.05).(2) The plasma levels of copeptin in moderate stenosis group and severe stenosis group were higher than those in control group and mild stenosis group(P<0.05). There were not significant differences between severe stenosis group and moderate stenosis group(P>0.05). There were also not significant differences between the control group and the mild stenosis group(P>0.05). Conclusion:The plasma levels of copeptin and the incidence of CHD in diabetics were positively correlated. The plasma levels of copeptin and the severity of the coronary artery lesions in diabetics were positively correlated. |
[1] LAND H,SCHUTZ G,SCHMALE H,et al.Nucleotide sequence of cloned cDNA encoding bovine arginine vasopressin-neurophysin Ⅱ precursor[J].Nature,1982,295(5847):299-303.
[2] BANKIR L,BARDOUX P,AHLOULAY M.Vasopressin and diabetes mellitus[J].Nephron,2001,87(1):8-18.
[3] RIPHAGEN I J,BOERTIEN W E,ALKHALAF A,et al.Copeptin,a surrogate marker for arginine vasopressin,is associated with cardiovascular and all-cause mortality in patients with type 2 diabetes(ZODIAC-31)[J].Diabetes Care,2013,36(10):3201-3207.
[4] MELLBIN L G,RYDEN L,BRISMAR K,et al.Copeptin,IGFBP-1,and cardiovascular prognosis in patients with type 2 diabetes and acute myocardial infarction:a report from the DIGAMI 2 trial[J].Diabetes Care,2010,33(7):1604-1606.
[5] ZELLWEGER C,WILDI K,TWERENBOLD R,et al.Use of copeptin and high-sensitive cardiac troponin T for diagnosis and prognosis in patients with diabetes mellitus and suspected acute myocardial infarction[J].Int J Cardiol,2015,190:190-197.
[6] 彭朝胜,曹悦鞍,杨璐.老年糖尿病隐匿性心肌缺血患者的动态血糖分析[J].现代医学,2012,40(5):546-548.
[7] HOLMES C L,LANDRY D W,GRANTON J T.Science review:vasopressin and the cardiovascular system part 2-clinical physiology[J].Crit Care,2004,8(1):15-23.
[8] BABAR S I,BERG R A,HILWIG R W,et al.Vasopressin versus epinephrine during cardiopulmonary resuscitation:a randomized swine outcome study[J].Resuscitation,1999,41(2):185-192.
[9] MORGENTHALER N G,STRUCK J,ALONSO C,et al.Assay for the measurement of copeptin,a stable peptide derived from the precursor of vasopressin[J].Clin Chem,2006,52(1):112-119.
[10] ENHORNING S,WANG T J,NILSSON P M,et al.Plasma copeptin and the risk of diabetes mellitus[J].Circulation,2010,121(19):2102-2108.
[11] ENHORNING S,SJOGREN M,HEDBLAD B,et al.Genetic vasopressin 1b receptor variance in overweight and diabetes mellitus[J].Eur J Endocrinol,2016,174(1):69-75.
[12] HOLMES C L,LANDRY D W,GRANTON J T.Science review:vasopressin and the cardiovascular system part 1——receptor physiology[J].Crit Care,2003,7(6):427-434.
[13] ENHÖRNING S,HEDBLAD B,NILSSON P M,et al.Copeptin is an independent predictor of diabetic heart disease and death[J].Am Heart J,2015,169(4):549-556.e1.
[14] DIEPLINGER B,GEGENHUBER A,HALTMAYER M,et al.Evaluation of novel biomarkers for the diagnosis of acute destabilised heart failure in patients with shortness of breath[J].Heart,2009,95(18):1508-1513. |
